To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


View sample alert

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Departmental Publication (Transparency)
Home Office

Apr. 24 2023

Source Page: Non-technical summaries granted in 2022
Document: Non-technical summaries: projects granted in 2022, January to June (PDF)

Found: We are constantly looking for minimally invasive ways of collecting samples or data.


Written Question
Cancer: Medical Treatments
Tuesday 21st March 2023

Asked by: George Howarth (Labour - Knowsley)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has taken recent steps with NHS England to help support NHS trusts to make contractual arrangements for minimally invasive cancer therapies.

Answered by Helen Whately - Minister of State (Department of Health and Social Care)

NHS England commissions selective internal radiation therapy (SIRT) as a treatment choice for patients with unresectable advanced hepatocellular carcinoma (HCC), in accordance with Technology Appraisal 688 and metastatic colorectal cancer (mCRC), in accordance with an NHS England clinical commissioning policy.

In total, following regional completion of contractual negotiations and changes, we expect that there will be 19 providers of SIRT in the National Health Service in England. Nine will offer SIRT as a treatment for both HCC and mCRC, a further nine will offer SIRT as a treatment for HCC only and a single provider will offer SIRT as a treatment for mCRC.


Departmental Publication (Transparency)
Home Office

Mar. 03 2023

Source Page: Non-technical summaries granted in 2021
Document: Non-technical summaries: projects granted in 2021, July to December (PDF)

Found: CSF is obtained via a quick, minimally invasive surgical procedure under general anaesthetic so that


Deposited Papers

Feb. 16 2023

Source Page: A phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals. (3 docs).
Document: Clinical_Study_Report_Part_1.pdf (PDF)

Found: In addition, with the currently available therapies for the irtreatment, many individuals with chronic


Tweet
House of Lords - @UKHouseofLords
6 Feb 2023, 10:16 a.m.

Increasing the access to minimally invasive cancer therapies is the last topic of today’s #LordsQs in a question from Lord Aberdare. 📺 Watch online from 3.05pm https://t.co/cszlVQNMfw 4/4 https://t.co/crJnX137d2

Link to Original Tweet


Scheduled Event - Monday 6th February
View Source
Lords - Oral questions - Main Chamber
Increasing the access to minimally invasive cancer therapies
MP: Lord Aberdare
Lords Chamber
Cancer Therapies Access - Mon 06 Feb 2023
No Department present

Mentions:
1: Lord Aberdare (CB - Excepted Hereditary) invasive cancer therapies. - Speech Link
2: Lord Evans of Rainow (CON - Life peer) invasive cancer therapies. - Speech Link
3: Lord Allan of Hallam (LDEM - Life peer) invasive cancer therapies. - Speech Link
4: Lord Evans of Rainow (CON - Life peer) invasive cancer therapies. - Speech Link
5: Lord Aberdare (CB - Excepted Hereditary) invasive cancer therapies. - Speech Link


Written Question
Cancer: Health Services
Thursday 5th January 2023

Asked by: Greg Smith (Conservative - Buckingham)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is making to ensure there is sufficient infrastructure in Cancer Alliances to help deliver minimally invasive cancer therapies across England.

Answered by Helen Whately - Minister of State (Department of Health and Social Care)

NHS England’s specialised commissioning team have been undertaking work to expand the number of providers offering minimally invasive cancer therapies, such as selective internal radiation therapy.

The market engagement and Prior Information Notices have now been completed, with regional teams now putting in place the necessary contractual arrangements with National Health Service trusts. This work is also being completed ahead of the delegation of commissioning responsibilities to integrated care boards.


Non-Departmental Publication (News and Communications)
Competition and Markets Authority

Oct. 12 2022

Source Page: Private healthcare market investigation
Document: Final report - appendices Part 1 (PDF)

Found: In addition, the Agreement extended the referral obligations to invasive and non -invasive cardiology


Non-Departmental Publication (News and Communications)
Competition and Markets Authority

Oct. 12 2022

Source Page: Private healthcare market investigation
Document: Final report - appendices Part 3 (PDF)

Found: Oncology The agreed maxima for the supervision of chemotherapy and other supportive therapies have